MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Home・Aktien・BioNTech SE ADR

BioNTech SE ADR

Geschlossen

BrancheGesundheitswesen

91.9 -1.48

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

89.96

Max

93.69

Schlüsselkennzahlen
By Trading Economics
Einkommen	143M 301M
Verkäufe	-55M 1.2B
EPS	1.08
Gewinnspanne	25.311
Angestellte	6,772
EBITDA	253M 464M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+49.55% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Mai 2025

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-3.3B 23B
Vorheriger Eröffnungskurs	93.38
Vorheriger Schlusskurs	91.9

Nachrichtenstimmung

By Acuity

57%

43%

326 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

88.78 / 95.61 Unterstützung & Widerstand

BioNTech SE ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

BioNTech SE ADR Prognose

Kursziel

By TipRanks

49.55% Vorteil

12-Monats-Prognose

Durchschnitt 139.56 USD 49.55%

Hoch 171 USD

Tief 110 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für BioNTech SE ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

17 ratings

Buy

Halten

Sell

Basierend auf 17 Analysten, die in den letzten 3 Monaten Aktienbewertungen für BioNTech SE ADR – Dist abgegeben haben.

Technischer Score

By Trading Central

88.78 / 95.61Unterstützung & Widerstand

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Stimmung

By Acuity

326 / 386 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac